SEHK:1061Biotechs
Essex Bio Technology SEHK 1061 Margin Drift Tests Bullish Undervaluation Narrative
Essex Bio-Technology (SEHK:1061) has opened FY 2025 with first half revenue of HK$876.5 million and basic EPS of HK$0.29, setting the tone for how investors will read the latest set of numbers. The company has seen revenue move from HK$828.5 million in 1H 2024 to HK$858.2 million in 2H 2024 and then HK$876.5 million in 1H 2025, while basic EPS shifted from HK$0.28 to HK$0.26 and then HK$0.29 over the same periods. This gives a clear view of how the top and bottom lines are tracking into the...